Prognostic Factors in Chronic Myeloid Leukemia. Relationship with Interferon and Bone Marrow Transplantation

References

• Sokal J. E., Baccarani M., Russo D., Tura S. Staging and prognosis in chronic myelogenous leukemia. Sem. Hematol. 1988; 25: 49–61
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Keating M. J., Smith T. L., Talpaz M., McCredie K. B. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am. J. Med. 1990; 88: 1–8
   PubMed Web of Science ®Google Scholar
• Italian Cooperative Study Group on Chronic Myeloid Leukemia. Prospective confirmation of a prognostic classification for Ph+ chronic myeloid leukemia. Br. J. Haematol. 1988; 69: 463–466
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: the value of early evaluation of the course of the disease. Ann. Hematol. 1991; 63: 307–314
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group on Chronic Myeloid Leukemia. A prospective comparison of α-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. Haematolog. 1992; 77: 204–214
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer 1977; 35: 1–39
   PubMed Web of Science ®Google Scholar
• Cox D. R. Regression models and life tables. J. Stat. Soc. 1972; 34: 187
   Web of Science ®Google Scholar
• Apperley J. F., Mauro F. R., Goldman J. M., Gregory W., Arthur C. K., Hows J., Arcese W., Papa G., Mandelli F., Wardle D., Gravett P., Franklin M., Bandini G., Ricci P., Tura S., Iacone A., Torlontano G., Heit W., Champlin R., Gale R. P. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br. J. Haematol. 1988; 69: 239–245
   PubMed Web of Science ®Google Scholar
• Champlin R. E., Goldman J. M., Gale R. P. Bone marrow transplantation in chronic myelogenous leukemia. Sem. Hematol. 1988; 25: 74–80
   PubMed Web of Science ®Google Scholar
• Goldman J. M., Gale R. P., Horowitz M. M., Biggs J. C., Champlin R. E., Gluckman E., Hoffmann R. G., Jacobsen S. J., Marmont A. M., McGlave P. S., Messner H. A., Rimm A. A., Rozman C., Speck B., Tura S., Weiner R. S., Bortin M. M. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Ann. Int. Med. 1988; 108: 806–814
   PubMed Web of Science ®Google Scholar
• Sullivan K. M., Weiden P. L., Storb R., Witherspoon R. P., Fefer A., Buckner C. D., Anasetti C., Appelbaum F. R., Badger C., Beatty P., Bensinger W., Berenson R., Bigelow R., Cheever M. A., Clift R., Deeg H. J., Doney K., Greenberg P., Hansen J. A., Hill R., Loughran T., Martin P., Neiman P., Petersen F. B., Sanders J., Singer J., Stewart P., Thomas E. D. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720–1728
   PubMed Web of Science ®Google Scholar
• Horowitz M. M., Gale R. P., Sondel P. M., Goldman J. M., Kersey J., Kolb H., Rimm A. A., Ringden O., Rozman C., Speck B., Truitt R. L., Zwaan F. E., Bortin M. M. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Sokal J. E., Cox E. B., Baccarani M., Tura S., Gomez G. A., Robertson J. E., Tso C. Y., Braun T. J., Clarkson B. D., Cervantes F., Rozman C., the Italian Cooperative CML Study Group. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63: 789–799
   PubMed Web of Science ®Google Scholar
• Tura S., Baccarani M., Zaccaria A. Chronic myeloid leukemia. Haematologica 1986; 71: 169–176
   PubMedGoogle Scholar
• Fefer A., Cheever M. A., Thomas E. D., Boyd C., Ramberg R., Clucksberg H., Buckner C. D., Storb R. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N. Eng. J. Med. 1979; 300: 333–337
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H. M., McCredie K., Trujillo J. M., Keating M. J., Gutterman J. U. Hematologic remission and cytogenetic improvement induced by re-combinant human interferon alpha in chronic myelogenous leukemia. N. Eng. J. Med. 1986; 314: 1065–1069
   PubMed Web of Science ®Google Scholar
• Alimena G., Morra E., Lazzarino M., et al. Interferon alpha-2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent daily administration. Blood 1988; 72: 642–647
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H., Kurzrock R., Trujillo J. M., Gutterman J. U. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann. Int. Med. 1991; 114: 532–538
   PubMed Web of Science ®Google Scholar
• McGlave P. B., Beatty P., Ash R., Hows J. M. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases. Blood 1990; 75: 1728–1732
   PubMed Web of Science ®Google Scholar